National Stem Cell Distribution Doubled in 5 Years... "Expectations for Rare Disease Treatment Development"

The National Stem Cell Bank under the Korea Disease Control and Prevention Agency's National Institute of Health announced on the 20th that, following the provision of a total of 133 stem cell lines to 49 research institutions and companies last year, it will newly distribute four lines of disease patient-derived and fluorescently expressed stem cells starting this year.

Stem cells are cells capable of differentiating into various types of cells that make up the human body and are essential resources for identifying the causes of rare and intractable diseases and developing new treatments. They are also utilized in various advanced regenerative medical technologies such as cell-based artificial blood, bioartificial organs, and gene therapy.

The National Stem Cell Bank provides researchers with quality-verified stem cells. The newly distributed stem cells this year include the fluorescently expressed induced pluripotent stem cell line (E-cadherin) and three disease patient-derived induced pluripotent stem cell lines (LGMD, Down syndrome, Rett syndrome).

Among these, disease patient-derived stem cells can be used to analyze the causes of diseases such as muscular dystrophy, Down syndrome, and Rett syndrome and to develop personalized treatments.

The number of stem cell lines provided by the National Institute of Health to research institutions and companies reached 133 last year, showing a 1.8-fold increase compared to the average of the past five years, indicating that research utilizing domestic stem cells is actively progressing. The institutions that received stem cell distributions were universities with 36 cases (74%), companies with 10 cases (20%), and research institutes with 3 cases (6%).

Park Hyun-young, director of the National Institute of Health, stated, "The National Stem Cell Bank will do its best to develop and provide resources tailored to researchers' needs, such as clinical-grade stem cells, to support domestic stem cell research and the practical application of regenerative medicine."

This content was produced with the assistance of AI translation services.